Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353838 | 0.85 | ALDH1A1 (0.42) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL11039359 | 0.85 | ALDH1A1 (0.42) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL1194386 | 0.84 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL271468 | 0.83 | PNMT (0.54) | ALDH1A1KDM4EMAPTSMN1; SMN2KMT2A | |
| SCHEMBL3028541 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL24011712 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL496738 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL1645990 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL513341 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL513342 | 0.80 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190825-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | BIOCON LIMITED (IN) | 2024-06-13 | — | — | US | claimed |
| EP-4313048-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | Biocon Limited (IN) | 2024-02-07 | — | — | EP | claimed |
| WO-2022201079-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | BIOCON LIMITED (IN) | 2022-09-29 | — | — | WO | claimed |
| CN-104678028-A | Pretreatment and detection method for biogen amine neurotransmitter and detection kit | INST PHARM & TOXICOLOGY AMMS | 2015-06-03 | — | — | CN | claimed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025120168-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CRYPTOSPORIDIUM INFECTIONS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) | 2025-06-12 | — | — | WO | disclosed |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| CN-115667226-B | Tricyclic compounds as EGFR inhibitors | 齐鲁制药有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| WO-1994018165-A1 | SULFONAMIDE COMPOUNDS AS OPIOID K-RECEPTOR AGONISTS | PFIZER INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-4988379-A | Pre- and postemergent | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
| US-4840661-A | Sulphonyliso(thio)urea derivatives and herbicidal use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-20 | — | — | US | disclosed |
| EP-0173957-B1 | SULFONYLISO(THIO) UREA DERIVATIVES | BAYER AG (DE) | 1989-01-18 | — | — | EP | disclosed |
| EP-0173957-A1 | Sulfonyliso(thio) urea derivatives | BAYER AG (DE) | 1986-03-12 | — | — | EP | disclosed |
| EP-0173317-A1 | Unsymmetrical sulfonyl guanidines | BAYER AG (DE) | 1986-03-05 | — | — | EP | disclosed |
| EP-0045423-B1 | PROCESS FOR THE ALPHA-HALOGENATION OF POSSIBLY SUBSTITUTED METHYL AROMATICS | BAYER AG (DE) | 1984-02-22 | — | — | EP | disclosed |
| EP-0045423-A1 | Process for the alpha-halogenation of possibly substituted methyl aromatics | BAYER AG (DE) | 1982-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190825-A1 | PROCESS FOR PREPARATION OF CABOZANTINIB | PDK1, PDHB, MPC2 | ALDH1A1 1148/4885KDM4E 1356/4885MAPT 839/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3045/4885KDM4E 2520/4885MAPT 4732/4885 |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP9 | ALDH1A1 4680/4885KDM4E 937/4885MAPT 187/4885 |
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | ALDH1A1 4265/4885KDM4E 1197/4885MAPT 1287/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | ALDH1A1 2373/4885KDM4E 1961/4885MAPT 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.